The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective

Posted by William L. Dahut, MD | Jan 2020

William L. Dahut, MD, presented “The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective” for the Grand Rounds in Urology audience in January, 2020.

How to cite: Dahut, William L. “The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective” January, 2020. Accessed Apr 2024. https://grandroundsinurology.com/the-expanding-world-of-germline-testing-for-prostate-cancer-a-clinical-trials-perspective/

The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective – Summary:

William L. Dahut, MD, CCR Scientific Director for Clinical Research for the National Cancer Institute, summarizes a talk he presented at the 2019 Philadelphia Prostate Cancer Conference on recent developments from clinical trials of germline testing for prostate cancer. He discusses current NCCN recommendations for prostate cancer, challenges in training and availability of genetic counselors, and previews an upcoming study of men with high genetic risk of prostate cancer.

This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:

Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations
A Urologist’s Perspective on Germline Testing
Integration of Germline Testing in Prostate Cancer Screening
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective

About The Author

William L. Dahut, MD

William L. Dahut, MD, received his MD from Georgetown University in Washington, DC. He completed clinical training in internal medicine at the National Naval Medical Center in Bethesda, Maryland, followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of the National Cancer Institute (NCI). Dr. Dahut worked as an attending physician in the NCI-Navy Medical Oncology Branch until 1995. He then joined the faculty of the Georgetown Lombardi Comprehensive Cancer Center before returning to NCI in 1998. Dr. Dahut’s primary research interest has been in the development of novel therapeutic strategies for the treatment of adenocarcinoma of the prostate. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy, and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment are active and demonstrate the ability to maintain a robust immunologic response. In 2009, Dr. Dahut was appointed as CCR Clinical Director. In this capacity, he oversees and assures the quality of medical care delivered to patients participating in CCR clinical trials. In 2012, Dr. Dahut was appointed as a CCR Deputy Director, and then in 2016 was selected to become the CCR Scientific Director for Clinical Research.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat